



PTO/SB/21 (6-98)

Please type a plus sign (+) inside the box.

Approved for use through 09/30/2000 OMB 0651-0031
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/730,174
	Filing Date	12/05/00
	First Named Inventor	RICHARD J. ZAHRADNIK
	Group Art Unit	1641
	Examiner Name	UNKNOWN
Total Number of Pages in This Submission	Attorney Docket Number	IMUNE-001A

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Charge Any Additional Fee Required, to Deposit Account No. 19-4330 <input checked="" type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69 and Accompanying Petition) <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below) COPY OF NOTICE TO COMPLY WITH REQUIREMENTS, RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS, CERTIFICATE OF MAILING, AND RETURN RECEIPT POSTCARD.
REMARKS		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual Name	MATTHEW A. NEWBOLES
Signature	
Date	11/14/01

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in a 1 envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on this date 11/14/01			
Typed or printed name	MICHELLE SCHROEDER		
Signature		Date	11/14/01

† SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231

3

Case No.: IMUNE-001A



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Richard J. Zahradnik)	Group No.:	1641
Serial No.:	09/730,174)	Examiner:	Unknown
Filed:	12/05/2000)		
For:	PTH 1-84 ANTIBODY PREPARATION)		

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON D C 20231

Dear Sir/Madam:

The following is responsive to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed September 14, 2001 in relation to the above-identified patent application. In response thereto, Applicant is filing the amendment accompanying herewith in order to comply with the requirements of 37 CFR 1.821-1.825. Specifically, Applicant has provided herewith a compact disc providing an initial computer readable form (CRF) copy of the sequence listings appearing in the application with the amendment directing its entry into the application. Applicants hereby


state that the content of the sequence listing information recorded in computer readable form is identical to the written sequence listing appearing in the present application and does not include any new matter.

Accordingly, Applicant respectfully submits that it is complied with the Notice to Comply mailed September 14, 2001, and requests confirmation that the present application will proceed to examination. Early notice to that effect is respectfully requested. To the extent any outstanding issues continue to exist or if further information is required, please direct such inquiries to Applicants' counsel listed below.

Respectfully submitted,

Date: 11/14/01

By:



Matthew A. Newboles

Registration No. 36,224

STETINA BRUNDA GARRED & BRUCKER

75 Enterprise, Suite 250

Aliso Viejo, CA 92656

(949) 855-1246



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/730,174	12/05/2000	Richard J. Zahradnik	IMUNE-001A

CONFIRMATION NO. 8045

007663
STETINA BRUNDA GARRED & BRUCKER
75 ENTERPRISE, SUITE 250
ALISO VIEJO, CA 92656

FORMALITIES LETTER



OC000000006558785

Date Mailed: 09/14/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

DOCKET NO.: IMUNE001A



CERTIFICATE OF MAILING


UNDER 37 CFR 1.8 OR 37 CFR 1.10

- ☒ I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

- ☐ I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, Express Mail No. on the date indicated below and is addressed to:

on November 14, 2001.
(Date)


Signature

MICHELLE SCHROEDER

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

1. Transmittal Form;
2. Copy of Notice to Comply with Requirements;
3. Response to Notice to Comply with Requirements (2 Pages);
4. Amendment (15 Pages);
5. Certificate of Mailing; and
6. Return Receipt Postcard.